The anti-MAG Autoantibodies ELISA has outstanding sensitivity and specificity. In a study with 68 involved patients, the anti-MAG Autoantibodies ELISA was considerably more sensitive compared to Western Blot (Kuijf M. et al., 2009).

High titers of IgM anti-MAG antibodies are associated with sensory motor demyelinating peripheral neuropathy. The possibility of MAG antibody involvement in a suspected neuropathy may essentially be ruled out if a MAG IgM negative result is obtained. Detection of MAG IgM antibodies by ELISA based on human MAG antigen is significantly more sensitive and specific than Western Blot or IFA assays using primate antigen (Jaskowsky T. et al., 2008; Kuijf M. et al., 2009).

Even low anti-MAG antibody titers can be measured with the anti-MAG Autoantibodies ELISA (otherwise negative in Western Blots) which is important since this may be suggestive for a different neuropathy.

The quantitative ELISA is the ideal tool to follow-up on anti-MAG antibody titers which is needed in new therapy concepts based on monoclonal antibodies (e.g. Rituximab).

Accuracy: Pre-coated microtiter plates.

Specificity: The use of highly purified human MAG results in best likelihood to detect all positive patients. Using microtiter plates with extremely low unspecific binding properties. No blocking proteins thus reducing the chance for false positive samples.

Reproducibility: Pre-measured standards and two controls ensure low inter-assay variation.

Standardization: Standard curve with standardized titer units.

Quantitation: Allowing therapy monitoring of therapeutic intervention (e.g. Rituximab).

• Instructions for use*
• More information
• Technical Information
• Literature